A Short Delay Is Still Bad News for AbbVie

The FDA extended the review for AbbVie's (NYSE: ABBV) Rinvoq as a treatment for psoriatic arthritis. On the surface, a three-month delay isn't a huge deal for the large drugmaker. But as Fool.com Contributors Brian Orelli and Keith Speights discuss in this video from Motley Fool Live, recorded on March 22, the extension could be a sign the agency is worried about the side effects of Rinvoq and other JAK inhibitors.

Continue reading

Source Fool.com